multicenter study to prove that co-administration of gemcitabine, erlotinib and Hyangsayukgunja-tang extracts is improved the quality of life including pain and anorexia in patients with pancreatic cancer.

The effect of co-administration of Hyangsayukgunja-tang extracts to chemotherapy on the QoL in patients with pancreatic cancer - multicenter study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CRIS

Registry ID

KCT0001407

Enrollment

Registered

2015-03-10

Start date

2015-03-09

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : 1. Co-administration group Gemcitabie: 1000mg/m IV given on Day 1, 8 and 15th. erlotinib: 100mg PO Qd, HS, on Day 1 to 28 Hyangsayukgunja-tang extracts: 1pack PO Tid, on Day 1 to 28, 30min post

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Selection Criteria (meeting all of the following conditions) 1. Admitted or outpatient pancreatic cancer patient who is currently on or scheduled for gemcitabine, erlotinib treatment. 2. Patient with ECOG performance 2 or less 3. Age over 20yrs old and under 80yrs old 4. No damage to cognitive ability 5. Self determined participation with written consent signed by the patient or legal guardian. 6. Patient who can be followed during the trial period

Exclusion criteria

Exclusion criteria: Exclusion Criteria(satisfy any one of the following conditions) 1. Pancreatic cancer patient who is scheduled to have a surgical treatment after chemotherapy 2. patient with gastrointestinal obstruction requiring surgical treatment. 3. Hypertensive patient whose blood pressure is not controlled well with medication. 4. Hepatic or renal function test value exceeding 3times that of normal limit or AST, ALT over 200IU/L, Creatinine 3.4mg/dl or higher. 5. Patient with severe edema. 6. Failure of patient to give a written consent. 7. Patient who is determined unfit for this study due to poor physical or mental status by study conductor.

Design outcomes

Primary

Measure	Time frame
Pain rating scale;Quality of Life (EORTC QLQ-C30)	—

Secondary

Measure	Time frame
ghrelin, obstatin;survival, adverse events of chemotherapy (nausea/vomiting, thrombocytopenia, skin rash)	—

Countries

Korea, Republic of

Contacts

Public ContactAeryun Choi

Daegu Haany University

nadia2144@naver.com+82-53-770-2079

Outcome results